Memantina Aurovitas (Memantine Hydrochloride)

Memantina Aurovitas is an NMDA receptor antagonist used in the management of Alzheimer’s disease and related cognitive decline.

• Alzheimer’s disease (moderate to severe): helps maintain cognition and daily functioning in affected patients.
• Behavioral symptoms of Alzheimer’s disease: may reduce agitation and aggression associated with the condition.
• Functional decline in Alzheimer’s disease: supports activities of daily living and slows functional deterioration.

• Memantine Hydrochloride acts as a non‑competitive antagonist at the NMDA (N‑methyl‑D‑aspartate) receptor, binding to the receptor-associated ion channel. By reducing excessive calcium influx, it limits excitotoxic neuronal injury that contributes to cognitive decline in Alzheimer’s disease, thereby helping to preserve neuronal function and synaptic plasticity.

Common Side Effects

• Dizziness: mild to moderate sensation of light‑headedness.
• Headache: transient pain often reported during initiation.
• Constipation: reduced bowel movements, manageable with diet.
• Fatigue: feeling of tiredness or reduced energy.
• Hypertension: occasional increase in blood pressure.
• Confusion: temporary disorientation, especially in early treatment.

Serious or Rare Side Effects

• Seizures: rare occurrence requiring immediate medical attention.
• Stevens‑Johnson syndrome: severe skin reaction, discontinue use.
• Hepatic dysfunction: elevated liver enzymes, monitor liver function.
• Cardiac arrhythmia: irregular heart rhythm, especially in patients with pre‑existing conditions.
• Suicidal thoughts: emergent mood changes, seek psychiatric evaluation.
• Severe hypotension: marked drop in blood pressure, may cause fainting.

Memantina Aurovitas should be used with caution in specific clinical situations.

• Renal impairment: dose adjustment may be required based on kidney function.
• History of seizures: monitor closely for increased seizure activity.
• Cardiovascular disease: observe blood pressure and heart rate regularly.
• Concurrent NMDA antagonists: avoid co‑administration to reduce additive neurotoxicity.
• Pregnancy and lactation: safety unknown; avoid unless benefits outweigh risks.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Memantina Aurovitas may interact with several medicines; careful review is advised.

Major Interactions (Avoid)

• Amantadine: additive NMDA antagonism may increase neurotoxicity.
• Ketamine: combined NMDA blockade can cause severe central nervous system effects.
• Other NMDA antagonists (e.g., dextromethorphan): risk of additive toxicity.

Moderate Interactions (Monitor Closely)

• Antihypertensives: may enhance hypotensive effect, monitor blood pressure.
• Diuretics: increased risk of dehydration and dizziness.
• CNS depressants (e.g., benzodiazepines): may increase sedation and impair coordination.